Tag: allergy

For media and investors only

The global birch allergy market is experiencing robust growth due to increasing cases of allergic rhinitis from birch pollen and advancements in treatments like immunotherapy. Rising awareness and improved healthcare infrastructures in key regions such as the U.S., U.K., and Germany drive market expansion. Key therapies, including antihistamines and sublingual immunotherapy, are evolving alongside biologics and targeted treatments for severe cases. Despite challenges like high costs and regulatory hurdles, strategic partnerships and R&D in biologics are shaping the market. Ongoing innovations and digital health integrations are set to enhance patient outcomes globally.

Lægemiddelstyrelsen har netop godkendt Itulazax, den første tabletbaserede allergivaccination til behandling af børn og unge i alderen fem til 17 år med træpollenallergi i Danmark.

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

EAACI : Le Dupixent a démontré sa supériorité par rapport au Xolair (omalizumab) dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant dans la toute première étude respiratoire de phase 4 en comparaison directe jamais présentée

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints

HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company’s Phase 2 clinical trial in chronic spontaneous urticaria (CSU). Angioedema, characterized by swelling of the deeper dermal layers of the skin and mucous membranes, is a painful, debilitating symptom of CSU that has significant impact on quality of life. It commonly affects the face (lips and eyelids), hands, feet, and genitalia but can also involve the tongue, uvula, soft palate, and pharynx¹.